P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Table 4

One-year rates of adverse events.

	Clopidogrel, n (%)	Ticagrelor, n (%)		Prasugrel, n (%)
Mortality	622 (4.3)	12 (2.1)	0.01	18 (3.6)	0.44
Myocardial infarction	817 (5.7)	31 (5.5)	0.80	22 (4.4)	0.23
Stroke	399 (2.8)	12 (2.1)	0.33	7 (1.4)	0.07
Bleeding events	519 (3.6)	17 (3.0)	0.43	14 (2.8)	0.33

Evaluated using the log-rank test with comparison group of clopidogrel.